Analysts Expect Avenue Therapeutics Inc (NASDAQ:ATXI) Will Post Earnings of -$0.32 Per Share

Share on StockTwits

Wall Street analysts expect Avenue Therapeutics Inc (NASDAQ:ATXI) to post earnings of ($0.32) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Avenue Therapeutics’ earnings, with estimates ranging from ($0.34) to ($0.30). Avenue Therapeutics posted earnings per share of ($0.25) during the same quarter last year, which indicates a negative year over year growth rate of 28%. The firm is scheduled to issue its next earnings results on Wednesday, November 13th.

On average, analysts expect that Avenue Therapeutics will report full-year earnings of ($1.79) per share for the current year, with EPS estimates ranging from ($1.83) to ($1.75). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.15) to ($0.77). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Avenue Therapeutics.

Avenue Therapeutics (NASDAQ:ATXI) last released its earnings results on Wednesday, August 14th. The company reported ($0.43) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.05.

Several research firms have commented on ATXI. ValuEngine upgraded Avenue Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Avenue Therapeutics in a research report on Tuesday, May 14th.

NASDAQ ATXI traded down $0.08 during trading on Friday, hitting $5.80. The stock had a trading volume of 6,300 shares, compared to its average volume of 15,379. The company has a market capitalization of $97.29 million, a PE ratio of -2.76 and a beta of -0.41. The company’s 50-day moving average price is $6.04 and its two-hundred day moving average price is $5.49. Avenue Therapeutics has a 12 month low of $2.08 and a 12 month high of $7.98.

In related news, Director Neil Herskowitz purchased 5,000 shares of the stock in a transaction on Tuesday, June 18th. The shares were purchased at an average price of $5.86 per share, with a total value of $29,300.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joseph Walter Vazzano sold 4,688 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $5.59, for a total value of $26,205.92. Following the transaction, the chief financial officer now directly owns 59,038 shares in the company, valued at approximately $330,022.42. The disclosure for this sale can be found here. 5.00% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Spark Investment Management LLC acquired a new position in shares of Avenue Therapeutics during the 1st quarter worth approximately $144,000. BlackRock Inc. increased its holdings in shares of Avenue Therapeutics by 135.7% during the 2nd quarter. BlackRock Inc. now owns 39,933 shares of the company’s stock worth $251,000 after acquiring an additional 22,994 shares during the last quarter. Northern Trust Corp acquired a new position in shares of Avenue Therapeutics during the 4th quarter worth approximately $79,000. Finally, National Asset Management Inc. increased its holdings in shares of Avenue Therapeutics by 9.3% during the 2nd quarter. National Asset Management Inc. now owns 64,750 shares of the company’s stock worth $408,000 after acquiring an additional 5,500 shares during the last quarter. 7.04% of the stock is currently owned by hedge funds and other institutional investors.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

Featured Story: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Avenue Therapeutics (ATXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.